Discovery and structure–activity relationships of urea derivatives as potent and novel CCR3 antagonists
A. Nitta(Toray (United States)), Toshiya Takahashi(Tohoku University), Hirokazu Kubota(Astellas Pharma (Japan)), Koichiro Morihira(Astellas Pharma (Japan)), Takayuki Imaoka(Toray Industries, Inc. (Japan)), Mitsuaki Ohta(Tokyo University of Agriculture), Tatsuaki Morokata(Astellas Pharma (Japan)), Makoto Takeuchi(Kirin (Japan)), Shin‐ichi Tsukamoto(Astellas Pharma (Japan)), Hiroki Tomioka(Toray Industries, Inc. (Japan)), Ippei Sato(Astellas Pharma (Japan)), Yosuke Iura(Toray (United States))
Cited by 3
Related Papers
Effects of Hydroxychloroquine in Patients With Cutaneous Lupus Erythematosus: A Multicenter, Double‐Blind, Randomized, Parallel‐Group Trial
|Arthritis & Rheumatology|2016|119
Psoriasis and Antimicrobial Peptides
|International Journal of Molecular Sciences|2020|114
An In Vitro Test to Screen Skin Sensitizers Using a Stable THP-1–Derived IL-8 Reporter Cell Line, THP-G8
|Toxicological Sciences|2011|93
Cathelicidin promotes inflammation by enabling binding of self-RNA to cell surface scavenger receptors
|Scientific Reports|2018|84